WO1996029865A9 - Dispositif et procede de bilan et de reanimation d'organe - Google Patents

Dispositif et procede de bilan et de reanimation d'organe

Info

Publication number
WO1996029865A9
WO1996029865A9 PCT/US1996/004205 US9604205W WO9629865A9 WO 1996029865 A9 WO1996029865 A9 WO 1996029865A9 US 9604205 W US9604205 W US 9604205W WO 9629865 A9 WO9629865 A9 WO 9629865A9
Authority
WO
WIPO (PCT)
Prior art keywords
organ
fluid
data
controller
monitored
Prior art date
Application number
PCT/US1996/004205
Other languages
English (en)
Other versions
WO1996029865A1 (fr
Filing date
Publication date
Application filed filed Critical
Priority to AU53754/96A priority Critical patent/AU5375496A/en
Publication of WO1996029865A1 publication Critical patent/WO1996029865A1/fr
Publication of WO1996029865A9 publication Critical patent/WO1996029865A9/fr

Links

Definitions

  • the invention relates to a method and apparatus for perfusing an organ.
  • the perfusion of the organ permits the viability of the organ to be maintained and evaluated. Further, the perfusion of the organ by certain perfusates or fluids, including blood, can resuscitate the organ to a point where it is viable.
  • organs are known to be viable after as long as 30 to 60 minutes or more of warm ischemia, based on animal studies. In these studies, the flow of fluid to individual organs was selectively interrupted and then reestablished. However, when flow to the organ is interrupted by irreversible cardiac arrest or blood loss of a potential organ donor, organ resuscitation is more problematic. A machine into which an organ can be placed to permit the organ to be reperfused under controlled conditions is needed. A machine of this type would terminate the ischemic insult and allow the organ to begin to self-repair.
  • the device would also be useful if a potential donor has suffered cardiac arrest.
  • the device can be used between cardiac arrest and organ excision for perfusion in vitro, to flush donor organs in vivo and allow deterioration to be arrested and recovery to be initiated even before the organ is able to receive the benefit of perfusion in vitro.
  • MgCl 2 have been shown to be effective in the treatment of organ ischemia. These agents permit organ recovery after the ischemic period, but most of these agents are difficult to use in vivo due to their tendency to produce hypotension. Further, the deteriorated condition of the donor may not support circulation and perfusion for a sufficient period.
  • a practical working device would preferably include a disposable perfusion circuit that could be easily replaced and a compact unit that requires a relatively low perfusate volume. This is in direct contrast to a heart lung machine, which is designed to support an entire human patient.
  • a perfusion device containing a disposable circuit with a minimal perfusate volume has not been previously described.
  • organ transplantation field Another desirable feature for the organ transplantation field is a means which can assess the viability of an organ prior to transplantation. Recently, claims have been made that organ vascular resistance provides an adequate test of organ viability. These claims must be evaluated in the light of a vast amount of literature which states the contrary.
  • Normothermic perfusion apparatus previously described does not control environmental temperature. All the emphasis had been on controlling temperature of the perfusate. Previously described apparatus has not considered the significance of ambient humidity. Further, there has been no consideration of organ surface drying. Finally, previous apparatus has not provided a sheltered environment to minimize the chance of bacterial contamination.
  • the instant invention provides a perfusion apparatus and method for perfusing organs which overcome the above noted deficiencies of conventional perfusion apparatuses and methods.
  • the invention provides a perfusion apparatus and method with an automatically controlled and monitored fluid system.
  • the system includes a controller and monitors for the organ and the fluid.
  • the controller measures the viability of an organ, as well as measuring and controlling various characteristics of the perfusion fluid.
  • the perfusion system may be made of blood- compatible materials, although fluids other than blood can be used.
  • Useful perfusates include fluids selected from the group comprising blood, modified blood, ordinary crystalloid, modified crystalloid and oxygen-carrying crystalloid.
  • pharmaceutical agents, physiological agents and fixatives may be used.
  • Figure 1 is a schematic drawing of the perfusion system according to an embodiment of the invention.
  • Figure 2 is a drawing of a vascular immobilization/organ transport platform according to an embodiment of the invention.
  • Figure 3 is a drawing of an embodiment of the invention permitting the apparatus to be used in vivo prior to, during, and after transfer of an organ perfused in vivo to the in vitro apparatus.
  • Figures 4A, 4B, and 4C are drawings of a three-way occluding valve according to an embodiment of the invention.
  • Figure 5 shows an alternative embodiment of a three-way occluding valve.
  • Figure 6 displays the results of a recent experiment as an example of the functioning of the device and of the software that operates it.
  • Figure 7 displays the results of another experiment as a further example of the functioning of the device and the software that operates it.
  • Fig. 8 illustrates graphs representing parameters monitored during blood perfusion of an isolated kidney for the experiment of Fig. 7.
  • Figs. 9-16 illustrate graphs representing various parameters monitored during blood perfusion versus time.
  • Fig. 17 illustrates an alternative embodiment of a vascular immobilization/organ transplant platform.
  • the perfusion apparatus has a modular construction that is easy to assemble and disassemble.
  • the perfusion apparatus also provides for a disposable, sterile and optionally low-volume (to reduce the volume of blood or fluorocarbon needed) fluid system that is suitable for use on human or animal organs that may be later transplanted. Fluid systems having different volumes may be provided for different sized organs.
  • the modular fluid system permits a sterile and economical construction from known components.
  • Preferred embodiments include an organ transfer platform, preferably a position-adjustable platform.
  • the platform eliminates the need for direct handling of the organ.
  • the platform prevents the organ from changing orientation after removal from the donor and before placement in the perfusion apparatus.
  • the platform presents the organ in a flexible manner which facilitates connection of the organ to the apparatus.
  • the platform can also prohibit unwanted and potentially hazardous vascular motions.
  • Artery and vein positions can be adjusted according to the natural requirements of each organ. These positions are then firmly held in position avoiding any danger to the organ during attachment to the perfusion system.
  • Fluid can be moved through the system by a pump which is non-traumatic to blood or other synthetic or natural perfusion fluids such as emulsions.
  • a computer controlled adjustable piston-cylinder blood pump is preferred. However, other types of pumps can be used if desired.
  • the pump controls the pressure of the infused fluid in the fluid system.
  • the apparatus can control independently the infusion of nutrients, drugs and alternate perfusates into the fluid in the fluid system, thus permitting the organ to receive vital and beneficial material.
  • the controller can actuate valves and/or pumps connected to liquid sources. This is especially beneficial if the organ is damaged so that the addition of the nutrients or pharmaceutical agents can resuscitate the organ.
  • the use of a blood pump also allows for a pulsating perfusion to simulate the natural in vivo environment of the organ.
  • the pressure pulse wave can be readily adjusted manually and/or by computer as desired, from a low pulse amplitude to a high pulse amplitude.
  • the use of a computer to control the perfusion apparatus and process permits the mean blood pressure, systolic blood pressure, and diastolic blood pressure, along with other parameters of interest to be determined, controlled, displayed, and logged in real time, in any manner desired. This is especially beneficial in determining the status and viability of the organ.
  • the invention further permits facile, sterile connection of a disposable circuit to the blood pump and the sensors of the fluid system.
  • a facile calibration of fluid sensors and pressure transducers is readily achieved with the computer controlled perfusion apparatus.
  • the apparatus can also monitor organ functions.
  • Organ function such as urine flow rate (when pertinent), vascular resistance, oxygen consumption, acid and CO 2 production and the like can be continuously or intermittently measured. This permits a ready viability assessment of the organ based on the functioning of the organ. Further, simultaneous measurement and display of pO 2 , pCO 2 , pH, temperature, organ weight (edema) and the like can be accomplished by the computer controlled perfusion apparatus. Electrical cross-talk can be avoided, which is advantageous.
  • the invention can further provide automated, prearranged urine and blood collection.
  • Fraction collectors permit renal clearance calculations to be carried out either acutely, if in-house serum/urine analysis capability exists, or during subsequent organ storage. Similar calculations can be made for other organs.
  • automated sample collection by the computer controlled perfusion apparatus avoids technician errors.
  • the computer controlled perfusion apparatus can also continuously replace "lost" fluid volume. Fluid lost as urine (or bile, pancreatic duct fluid, etc. depending on the organ) can be replenished at the same rate volume is lost. Uncompensated loss of volume will result in altered hematocrit, plasma protein concentration, perfluorochemical emulsion concentration, etc.
  • the continuous replacement can be accomplished by sensing the lost volume directly or indirectly, and activating an appropriate pump or pumps to supply additional solution to the perfusion system. This permits avoidance of the recycling of excreted fluids which may damage the organ.
  • the device is also capable of continuously replacing substrates in the perfusate or fluid at the rate they are consumed by the perfused organ.
  • the replacement can be based on standard rates of substrate utilization or on rates of substrate utilization previously measured in similar organs. Substrate replacement and volume replacement can be accomplished independently of each other.
  • the computer controlled system can be adjusted to permit either a gradual or abrupt change in the perfusate.
  • a gradual change would be gradual replacement of a low-viscosity crystalloid perfusate with leukocyte and platelet depleted blood.
  • An abrupt change could include a switch from blood to saline and/or a switch from saline to fixative for experimental runs, with collection of fixative or other perfusate in an auxiliary reservoir.
  • the perfusion apparatus can challenge organs by infusing pharmaceutical, physiological or rescue agents under the control of the controller.
  • the controller can control the onset time, administration rate, rest periods, etc. of this infusion.
  • the perfusion apparatus can be used to perfuse a cadaver donor.
  • the perfusion apparatus can then accommodate one or more organs from the donor as organ procurement proceeds and is completed.
  • the perfusion apparatus or portions thereof, especially including the connection to an organ may be enclosed in a sterile or semi-sterile climate-controlled enclosure, cabinet or incubator.
  • the enclosure can preferably maintain an internal air temperature -with a heating element and/or internal humidity using small amounts of sterile water.
  • an additional organ box, into which an organ transport platform fits, can shelter the organ from contact with condensed water and from bacterial contamination.
  • the enclosure may be sterilized between uses, such as with disinfectants and/or an internal UV light.
  • the enclosure is preferably configured to position the organ to be visible at all times during the perfusion.
  • the enclosure may have doors to render the organ accessible from one, two or more sides. Transparent surfaces of the enclosure may be covered to protect personnel during UV sterilization.
  • the apparatus may be provided with microscopy/image analysis capability. This permits a non- invasive viability assessment to be based on morphological and cell physiological measurements, for example fluorescent or colored tag measurements.
  • the advantages of a perfusion apparatus for organ resuscitation are numerous.
  • the perfusion apparatus can include a pump that will not be affected by hypotensive agents. Any desired intervention, no matter how unphysiologic, can be accomplished using such a apparatus.
  • the operator can use hypertonic perfusates to reverse cell swelling, high potassium perfusates to restore cell potassium, or perfusates containing red blood cells or perfluorochemicals, but devoid of platelets and leukocytes, to avoid thrombi and inflammatory reactions while supplying oxygen and time to permit organ lesions to heal.
  • the components used to construct the perfusion system may be selected from the list of parts and materials provided in Tables 1 and 2.
  • a separate interface board (the PBM-4 Minarik Process Control Module, Shingle Gibbs, Inc. Baltimore, Md) ran the Harvard Apparatus Blood Pump and was directly mounted inside the blood pump housing.
  • a custom electrical system was supplied by Eldex Inc. to allow drop detection by the computer.
  • Fig. 1 presents a schematic diagram of the perfusion system.
  • the fluid-conducting elements of the system may be prefabricated as one disposable pack that can be introduced into the equipment as a unit.
  • the system may also be composed in whole or in part of modules that can be connected by using sterile Luer LokTM fittings and piercing fittings, such as blood bag and blood bag tube spikes.
  • blood bag tubing spikes may be used to insert lines into mating inlet and outlet ports of pump 30.
  • a male or female Luer fitting may be used to effect this connection.
  • the tubing used is preferably blood-compatible tubing such as blood bag tubing, Tygon R tubing, or Silastic R tubing.
  • the organ 1 is atraumatically supported on a special organ holder and transport platform 2.
  • Platform 2 organizes the renal vessels after organ excision and prior to perfusion in vitro.
  • the organ transport platform 2 is placed into an organ container 3.
  • Container 3 provides general protection for the organ and may, when the organ is electrically excitable, such as a heart, be used to facilitate mounting of electrodes used to monitor and/or pace electrical activity. It also prevents platform 2 from contacting the top loading balance 4. This further ensures the sterility of organ 1.
  • the organ container 3 and the organ platform 2 are designed to allow free access to the organ 1. Openings in the container wall allow cannulae to enter and exit. Platform 2 and container 3 may be combined into a single unit if desired. The outer container 3 could be eliminated or replaced by a piece of stretched parafilm.
  • R A top-loading balance 4 measures and continuously monitors the weight of organ 1 to estimate the amount of tissue edema. For small organs, such as rabbit kidneys used in biological experiments, the organ 1 is weighed prior to placement on the transport platform 2. When the organ 1 and accompanying equipment are positioned on the top-loading balance 4, the weight is tared to zero. Total organ weight is then monitored as the initial organ weight plus the change in weight (organ edema) registered by the balance 4 after taring. For large human organs, it may be sufficient to tare the weight of the container 3 and platform 2 to zero and make a direct measure of organ weight, because minor factors such as influences of the cannula position on organ weight may be negligible for large organs.
  • Organ weight is registered by a direct connection between the balance 4 and a serial port of a computer 5.
  • the computer 5 controls and documents the perfusion.
  • the data could be transmitted by other equivalent means, if desired.
  • the incoming data are input as character strings.
  • the character strings are analyzed with a stored string recognition algorithm to isolate the information desired. This permits the desired information to be converted back to a number (the number of grams of organ edema) and passed to the portion of the program that requests the information.
  • the weight data, and all other data can be deposited into a spreadsheet or into a spreadsheet format by the computer 5.
  • a jack 45 is provided to lift or lower the balance 4 and the associated organ 1, platform 2, and container 3 to adjust the elevation because organs vary in size, shape, and vascular orientation.
  • the jack 45 may be motorized and may be controlled by a joystick located external to cabinet 42.
  • Cabinet 42 encloses the organ and permits the temperature-controlled, humidity-controlled environment to be established.
  • the inputs and outputs to the organ include an arterial inflow line 6, venous outflow line 7, and secretion/excretion line 8. Fluid or perfusate is delivered to the organ 1 from the arterial line 6 and drained from the organ 1 by the venous line 7.
  • the vein is cannulated in order to permit measurements of oxygen consumption, carbon dioxide production, and blood acidification as indices of the fundamental metabolic balance sheet of the organ 1. Correction for losses of oxygen and carbon dioxide in any secretions or excretions is not significant because the volume of secretions from organs, including urine flow in kidneys, is normally such a small fraction of total organ blood flow and because the oxygen and CO 2 carrying capacity of these secretions is low in comparison to blood.
  • Oxygen consumption, CO 2 production, and acid production are calculated from measurements of gas tensions and pH in the arterial line 6 at sensor bay 15 and in the venous line 7 at sensor bay 16 using standard formulas.
  • CDI sensor heads made by 3M Health Care, Tustin, California
  • CDI heads also measure arterial and venous temperatures, to check on temperature control and uniformity within the perfusion cabinet 42.
  • the CDI heads are connected to a readout device 17.
  • Readout device 17 sends a signal to the computer 5 via a serial port.
  • CDI sensors or equivalents are selected because they are able to collect the data without electrical interference.
  • reservoirs or containers 11 and 12 may be provided to hold fluid.
  • the fluid is significantly different in composition from the blood or other solution travelling through the system.
  • a waste collection reservoir 14 may be provided to drain undesired perfusate.
  • Elements 18 and 45 are pinch-type solenoid valves (such as the Model 100P2WNC valves sold by Bio-Chem Valve Co., East Hanover, NJ) capable of blocking lines 48 and 49.
  • pinch-type solenoid valves such as the Model 100P2WNC valves sold by Bio-Chem Valve Co., East Hanover, NJ
  • Valve elements 9, 10, 13, and 33-35 are preferably three-way (rather than two-way) valves. These valves may either occlude the tubing by pressing on the tubing from outside, in the manner of valve 18, or by conventional flow diversion mechanisms where perfusate actually travels through channels in the valve.
  • a flow- through valves e.g., valves such as NR Model 648T033 teflon-lined solenoid valves, Neptune Research, Maplewood, NJ.
  • These channels may be selected either manually, as with a three-way stopcock, or by computer via a selection of the position of an internal piston in the valve.
  • Flow through valves have two disadvantages: a) the material in the valves must be blood compatible, and b) the tubing leading to and from the valve cannot be continuous when using valves that are currently commercially available, because there is no way to insert a continuous tube into such a valve. Conventional valves made with blood-compatible material may be used, despite these disadvantages.
  • valves shown in Fig. 4A-4C or 5 are used that allow continuous tubing to be employed. Therefore, a single disposable tubing pack can be used. This allows flow diversion by external compression so the valve itself need not be made of a blood-compatible material.
  • Line 49 permits the sampling of blood.
  • Line 49 is preferably of narrow diameter to avoid the loss of perfusion pressure upon the activation of valve 18.
  • valve 18 is to be activated intermittently, rather than continuously for each blood sample collection for the same reason.
  • the present invention may be used not only to evaluate and resuscitate organs for clinical use, but also to conduct experiments on organ resuscitation and evaluation after other procedures.
  • Valves 9 and 13 are activated immediately thereafter so as to permit fluid from reservoir 11 to drain into arterial line 6, proceed through the organ 1, and exhaust to drain site 14 through valve 13.
  • reservoir 11 will contain saline to flush blood from the organ 1 that would otherwise become trapped in the organ by the fixative in 12.
  • valve 10 is activated to allow the contents of reservoir 12 (typically fixative) to flow through the organ instead of the contents of reservoir 11.
  • Fluid from reservoirs 11 and 12 may drain into the organ 1 under the influence of gravity.
  • the fluid may be propelled by a pump (not shown) placed between 9 and 10.
  • Reservoirs 11 and 12 are preferably within the temperature-controlled cabinet. Therefore, fixation can proceed without changing organ temperature.
  • valves 9 and 13 between the organ and sensor bays 15 and 16 results in the organ being fixed without contamination of the sensor heads, perfusion pump, pressure transducer, or other vulnerable and reusable system components with fixative.
  • Upstream of arterial sensor bay 15 is an entry site for arterial infusion line 48.
  • Line 48 permits the delivery of rescue drugs from syringe 46 under the control of computer-actuated syringe pump 47.
  • the use of a syringe and a syringe pump is not critical, another type of equivalent reservoir and fluid metering system being acceptable.
  • the infusion entry site is guarded by pinch valve 45 preventing the contamination of line 48 by perfusate and preventing unwanted contamination of the active perfusion circuit with drug.
  • Upstream of line 48 is the exit point for arterial blood sampling. This point is governed by pinch valve 18 and leads to the fraction collector 20 and the associated drop counter 19. Drop counter 19 is used to ensure collection of a consistent volume with each blood collection (typically about 2 ml). As noted above, line 49 is chosen to have a narrow diameter to limit pressure drops upon actuating valve 18. Valve 18 is also, as noted above, actuated and deactivated several times for each blood collection, if need be, to further ensure adequate maintenance of arterial perfusion of the organ during blood sample collection.
  • Line 49 is upstream of line 48 to avoid contamination of blood samples with infused drugs, and loss of infused drug into collected blood samples.
  • Transducer 22 Upstream of line 49 is a junction 21, which leads both to the pressure transducer 22 and toward the source of perfusate.
  • Transducer 22 sends a signal to, and receives excitation from, an interface 9b, between it and the computer 5.
  • the computer calibration for the pressure transducer may be checked at any time by reference to mechanical pressure transducer 24.
  • Transducer 24 is protected by a diaphragm 25 to avoid contamination with perfusate.
  • Element 26 is a coarse blood filter.
  • Element 27 is a coil of Silastic R tubing that serves as a gas exchange surface (oxygenator and CO 2 remover). Tubing 27 is surrounded by a gas pocket 28 in which oxygen from tank 29 flows to introduce oxygen and carry off carbon dioxide. It is not necessary and can even be detrimental to supply CO 2 gas to tubing 27. 100% oxygen or a mixture of oxygen and nitrogen is therefore recommended.
  • a three-way valve 33 is upstream from the oxygenator.
  • the pump 30 will draw solution either from bag 31 or bag 32, depending on whether or not valve 33 is actuated.
  • valve 33 By switching from bag 31 to bag 32 during a perfusion and actuating valve 13, it is possible to abruptly and essentially completely replace a given perfusate with another.
  • valve 33 by activating valve 33 intermittently, the perfusate in bag 31 can be gradually blended with the perfusate in bag 32. This can lead to either a full or a partial substitution of the first perfusate with the second perfusate over a predetermined time. If desired, additional bags and valves could be added to enable additional complexity using the same approach.
  • Valve 35 is complementary to valve 33.
  • any volume replacement or nutrient replacement should also be transferred from bag 31 to bag 32 using valve 35.
  • the fluid delivered for volume replacement from the reservoir 37 by the pump 36, and the vehicle for the nutrients in syringe 38, as delivered by computer-actuated syringe pump 39 must also be compatible with the perfusate composition of the bag 32. If it is not compatible, a similar three-way valve or a flow-through 3- way valve, would be need to be interposed between 36 and 37 to permit a different volume replacement solution to be chosen instead of the solution in reservoir 37 to ensure compatibility with the new perfusate. Fortunately, the volume of infused nutrient solutions is expected to be small enough, and the vehicle solution is expected to be universal enough, to preclude the need for separate nutrient solution infusions for separate perfusates most of the time.
  • Valve 34 is similar to valve 35 in that it controls which bag, 31 or 32, receives incoming fluid.
  • the incoming fluid is venous return from the perfused organ.
  • bags 31 and 32 are located vertically below or at the level of the organ 1, not substantially above it. This is to avoid creation of a substantial venous outflow pressure that would slow perfusion and promote organ edema.
  • the secretion collection line 8 leads to drop counter 40 in route to fraction collector 41.
  • the drop counter 40 is a standard unit used with laboratory fraction collectors. Its output is directed to the computer 5 though a custom electrical circuit specially designed to permit its voltage response to be input to the computer at high speed so that voltage peaks and valleys could be resolved and interpreted as overlapping pulses. Each pulse represents one drop. This procedure is necessary to allow drops to be resolved and accurately counted, particularly when the drops are closely spaced. This is important when perfusing kidneys, for example, since urine flow tends to be pulsatile, rapid volleys of drops interspersed with slower drop rates being normal. The results were converted from drops per unit time into volume per unit time using a measured calibration factor and optionally into volume per unit time per gram of original organ weight.
  • the overall perfusion system is divided into upper cabinet 42, which is temperature and humidity controlled, and lower cabinet 44, which is less controlled. Humidity is controlled in cabinet 42 with a humidifier 50.
  • the temperature is maintained through standard thermosetting mechanisms known in the art. If necessary the reservoir 37 and even pump 36, may be included in cabinet 42 to ensure temperature stability. However, the volumes delivered from pumps 39 and 47 are not sufficient to create thermal stability problems.
  • the invention provides for an organ transport/handling platform 2, as shown in Fig. 1, to prevent twisting of the vessels during transport to the apparatus.
  • the platform also prevents motions of the vessels during attachment to the apparatus.
  • the vessel- organizing features of the platform are of particular value in handling small organs in biological experiments.
  • the organ-cradling feature is of equal value for both large human organs and small animal organs.
  • the organ-handling platform is described in Fig.
  • the platform 216 includes an organ cradling area 217 and a cannula control area 218.
  • the cannula control area 218 consists of a main body 201 and a retainer bar 204.
  • the retainer bar 204 mates with the main body 201 by means of the hinge 205 and the thumbscrew 206.
  • Bar 204 may be pivoted up to allow organ cannulae to be laid on the floor 219 of the main body 201 without restriction of any kind on the lateral position or rotational orientation of these cannulae.
  • the bar 204 may then be lowered and locked in place with thumbscrew 206 or other suitable means to immobilize the cannulae and/or their associated tubing in the previously- selected, preferred positions.
  • the immobilization is attained by placing vertical downward pressure on the cannulae and/or tubing according to the relative heights of the cannulae or tubing cross-section and the gap 207, which is determined by the construction of the recess 219 receiving the bar 204.
  • the recess 219 is in the lateral wall of base portion 201.
  • the height of the gap 207 is selected to meet the requirements of the specific cannulae and/or tubing used. It should be chosen to apply sufficient pressure to immobilize the tubing and/or cannulae without collapsing the tubing/cannulae significantly.
  • the vertical elevation of the recess floor 222 and the bar 204 are selected to suit the type and size of the organ being perfused.
  • the vertical height of the vessels emerging from an organ 213 is not what is expected.
  • the floor 219 of base 201 is horizontal and at a fixed elevation, an angle can be imposed between the horizontal tip of the cannula near the organ and the organ vessel leading from the organ to the cannula tip. This angle may alter the flow through the organ and damage the organ vessel.
  • the base 201 is constructed to pivot within the organ cradle part 217. Thus a straight line path from the cannula tip to the organ can be achieved by altering the horizontal disposition of the cannula.
  • the organ cradle part 217 contains a fine mesh or other deformable surface 211.
  • the surface 211 allows the organ to sag slightly into recess 212. This cradles the organ in a hammock-type fashion and thereby reduces the force on any given surface element of the organ required to support the organ's weight.
  • Aperture 220 in wall 208 of organ cradler 217 allows the secretion cannula 221 to emerge from the device. Cannulae 221 is permitted to emerge at the position that best suits the anatomical requirements of the particular organ being perfused. The position of the ureter, for example, can be of extraordinary importance in governing urine flow rate.
  • Fig. 3 describes an application of the apparatus for use in vivo.
  • Lines 6 and 7 are made long enough to be extended sufficiently from cabinet 42 to be placed into the aorta and vena cava, or into one or more individual organ vessels (e.g., renal artery and vein) of the donor.
  • individual organ vessels e.g., renal artery and vein
  • Separate (single or multiple) individual fluid flow systems originating with arterial lines 45 are provided for collected organs.
  • a single pump may be used for a cadaver and for all perfused organs. However, if flow is to be registered for each individual organ, a separate pump will be required for each organ.
  • the first collected organ can be transferred to the cabinet while continuing cadaver perfusion. Activation of that particular system can be accomplished using the types of valves described above. Second, third, or later organs can be added to the machine as they are procured. The lines 6 and 7 of Fig. 2 can be excluded from the system when all organs have been collected. In Fig. 3, the reservoirs, pump, oxygenator, and tubing are enlarged to be appropriate for use on a cadaver.
  • tubing segment 402 leads to the organ while tubing segment 403 leads from the main perfusate source, and tubing segment 401 leads from the bags 11 and 12 as seen in Fig. 1.
  • the primary or normal flow is from 403 to 402, with 401 being blocked.
  • the secondary flow direction is from 401 to 402, with 403 being blocked.
  • Fig. 4A four arc-shaped fingers 404-407 are similarly shaped and shown end-on.
  • the fingers 404-407 project past the segments of the tubing.
  • Each finger 404- 407 is attached to a rod 408-411.
  • Each rod 408-411 can be rotated about its axis by a suitable means (not shown).
  • rod 408 is rotated clockwise and rod 409 is rotated counter-clockwise. This movement forces fingers 404 and 405 toward each other, thereby occluding tubing segment 401.
  • Tubing segments 402 and 403 remain unaffected.
  • the rod 409 is rotated clockwise and rod 411 is rotated counter-clockwise.
  • Rod 404 is also rotated counter-clockwise back to its "rest" position, shown in Fig. 4A. This removes deformation of tubing segment 401 without affecting tubing segment 402.
  • Finger 406 is not used during a perfusion, but may by used during preparation of the circuit prior to perfusion. With fingers 405 and 407 in their rest positions, rotating finger 404 counter-clockwise and finger 406 clockwise occludes the tubing segment 402, while segments 401 and 403 remain open. This configuration may be used to flush segment 401 with perfusate to remove air prior to attaching bags 11 and 12. In addition, simultaneous occlusion of segments 402 and 403 may allow bags 11 and 12 to be attached to the system without unwanted fluid flow from segment 401 to either 402 or 403.
  • finger 406 and rod 410 could be replaced by a support rod or platform for supporting the segment 402, in other embodiments.
  • fingers 406 and 407 could be joined together to form a single finger operated by a single rod, in another embodiment.
  • the valve of Fig. 4A is preferably operated by the computer 5.
  • Each finger 404-407 is operated independently. Fingers 404 and 405 can assume one of three positions. Fingers 406 and 407 can assume one of two positions. A four way valve could also be employed where fingers 406 and 407 would have a third position to occlude tubing in the direction of area 413.
  • Fingers 404-407 are attached to rods 408-411 in part by an end-to-end abutting arrangement and in part by an adapter segment 412. This arrangement is visible in Fig. 4B.
  • Fig. 4C shows a different version of the valve.
  • the fingers 404-407 are shaped like the four smoothed quadrants of a circle.
  • the fingers 404-407 continue to be mounted on the ends of the rods 408-411.
  • Fig. 5 shows another embodiment of the three-way occluding valve.
  • the tubing segments 501, 502, and 503 are occluded by direct pinching between pincher elements.
  • pinch elements 515 and 516 can occlude tubing segment 502.
  • valve 18 of Fig. 1 could be used. These valves are preferably modified to minimize dead spaces between the tubing junction between segments 502, 503 and 504 and the sites of the occlusion.
  • Fig. 6 presents the perfusion data for a recent experiment using a rabbit kidney.
  • the data are shown in the format displayed on our monitor in real time. All graphs have the same time base and are displayed as a series of parallel strips.
  • the organ used in the tests was a rabbit kidney.
  • the kidney was perfused with leukocyte and platelet depleted rabbit blood with some hemodilution with a saline/nutrient solution containing hydroxyethyl starch to combat edema.
  • Trace 1 shows organ weight demonstrating minimal edema formation with perfusion time.
  • Trace 2 shows that pressure was excellently controlled by the computer.
  • the computer registered systolic (upper thin line), mean (middle heavy line) and diastolic (lower thin line) pressure continuously.
  • the pressure was initially elevated to the target 90 mmHg level gradually to avoid pressure overshoot.
  • Pressure was maintained constant in Trace 2 despite continually improving blood flow, as evidenced by Trace 3.
  • the continually improving blood flow is evidence of organ damage reversal and increased organ viability.
  • Urine flow rate is shown in Trace 4. The urine flow rate shows continuous improvement after about 40 minutes.
  • Trace 5 shows the temperature being maintained at the 35-36 degree Fahrenheit target range. This range was chosen because slight hypothermia is known to favor repair in vivo and is advantageous. Any temperature from about 20 degrees to about 37 degrees Fahrenheit may permit organ function to be determined and improved.
  • Trace 8 shows that the pH was maintained near 7.4. This was maintained despite the high carbon dioxide, as seen in Trace 7.
  • Trace 10 shows a steady rise in the hematocrit toward the normal level. This was despite volume additions as indicated in Trace 11.
  • the volume addition was conducted manually in this experiment. This was done to test the ability of a human operator to judge the correction of the system volume.
  • the volume additions shown represent isolated additions rather than a continuous addition, which is possible with a computer.
  • the human operator succeeded in approximately stabilizing hematocrit after about 30 minutes, it is apparent that computer control could have been more effective throughout the experiment than was the human operator.
  • the significant increase in hematocrit observed was despite volume replacement, indicating that failure to replace lost volume would have led to much more significant rises in hematocrit, perhaps bringing hematocrit to the point where blood viscosity would have presented serious problems for the perfusability of the organ.
  • the blood perfusion apparatus allows a kidney be perfused with blood in a closed system for 2 hours with automated control of various parameters. In the experiments, eight freshly harvested kidneys were perfused and used as a control.
  • Blood perfusion apparatus A physiological environment is recreated in the blood apparatus. Blood is pumped by suitable pump, for example by a Harvard pulsatile blood pump, through a closed system of blood compatible tubing. The blood is stored in a 250 ml blood collection bag, for example, by Fenwal on a venous line. The blood circulates at constant pressure through the kidney, whose artery, vein and ureter have been canulated. Pressure is detected through a pressure transducer, for example, PX23 by Ohmeda, which signals a computer that in turns sets a pumping rate for the blood pump.
  • a pressure transducer for example, PX23 by Ohmeda
  • the blood is oxygenated by passing through a coil of siliconic tubing in an oxygen saturated chamber.
  • the gas composition of the blood is continually recorded by a blood gas analyzer, such as a CDI blood gas analyzer.
  • the system is equipped with a 40 micron microaggregate filter, for example, by Baxter on the arterial line.
  • the volume of urine produced is measured by a drop counter data, for example, by Eldex, and an equivalent volume of fluid is returned to the blood bag.
  • a drop counter data for example, by Eldex
  • an equivalent volume of fluid is returned to the blood bag.
  • the perfusate composition is kept constant.
  • a modified Weinberg solution reservoir is connected to a 0.22 micron filter, for exmaple, by Millipore, through a return line to the blood bag.
  • a roller pump for example, by Masterflex, is programmed so the pump rate is monitored according to the volume of urine produced.
  • the Weinberg solution allows to keep the electrolytes and hemotocrit at a constant level.
  • the system described above is positioned on top a water bath, and is covered. This maintains the required normothermic temperature and humidity.
  • Blood At least 100ml of blood was drawn from the ear median capillary of three different rabbits in a mixture of asprinc/heparinc (10mg and 1000 mg units). Platelets and white cells were removed by centrifugation to minimize their interference with the perfusion. The hemotocrit is reduced to 25%-30% by adding modified Weinberg solution.
  • the right kidney was harvested from a rabbit donor by standard procedure (see B.S. Khirababi and G.M. Fahy, Cryobiology 31, 10-25, 1994).
  • the kidney is flushed with an Eurocollins (EC) solution to remove residual blood, and stored in EC until it is connected to the blood perfusion apparatus, but not more than 2 hours.
  • the renal artery, vein and ureter are canulated, and the organ is placed on a stage platform. Before connection, the kidney is flushed with modified Weinberg solution to remove any residual EC.
  • the pressure is activated and is gradually increased to 90 mmHg.
  • Perfusion conditions are maintained as sterile as possible, for example, by autoclaving material, or cleaning up the disconnect parts with Tergazyme, rinsing them with MilliQ water and keeping them in closed containers.
  • the kidney is disconnected and immediately flushed with EC.
  • the kidney is stored in EC until retransplantation, but no longer than 40 min.
  • the transplantation is done on the left hand side of the rabbit after nephectomy on the left side kidney.
  • the kidney is perfused with 25-30% hematocrit blood oxygenated at a pressure of at least 120 mmHg.
  • the perfusion pressure is maintained and controlled at 90 mmHg for 2 hours.
  • Urine is collected by a fraction collector, and the volume measured. Fluid is returned to the blood in an amount equal to the measured volume. Blood samples are collected during the perfusion at time interval of 0, 15, 45, 75, 105 and 120 min. to determine the blood chemistry.
  • a computer file is generated after the perfusion and data can be graphed as in Fig. 7.
  • This system allows parameters to be followed, such as blood flow, arterial pressure, urine flow, oxygen consumption. It also allows observation of cortical changes. Oxygen consumption was also evaluated. At precise time intervals, blood and urine samples are collected and their chemistry is an indicator of renal function, such as glomerular filtration, protein exclusion and tubular reabsorption of various chemical substances.
  • a futher embodiment of an organ platform A is provided for the kidney.
  • the organ lies on a soft mesh 2000 that covers an aperture 2001 in a platform 2002.
  • the mesh 2000 is bonded to the platform 2002.
  • a renal artery cannula tubing 2100 and cannula (not shown) generally snaps into a recess 2003 in a positioning bar 2004. This assures a favorable orientation of the artery with respect to the kidney.
  • a further recess 2005 includes two cylindrical pathways through positioning bar 2004.
  • a venous cannula (not shown) or venous cannula tubing 2200 can be snapped into one of two closely-spaced positions of recess 2005 to assure a favorable orientation of the vein with respect to the kidney.
  • the circular cross-section of recess 2003 and the cylindrical pathways of recess 2005 permit the cannulas to be rotated clockwise or counterclockwise as needed to prevent twisting of the artery or vein, respectively.
  • the positioning bar 2004 may contain an extra channel 2006 for ducts such as, in this case, the ureter cannula.
  • Legs 2007 position the platform up off an underlying surface to reduce the chance of contamination from any nonsterile part of the underlying surface in sliding relationship to tilting bar 2008, which would be the platform, along side rail 2009.
  • Tilting bar 2008 would alter the angle of the kidney slightly to better orient the renal artery and vein with respect to apertures 2003 and 2005.
  • Tilting bar 2008 would be closely approximated to platform 2002 and need not be in the form of a bar. It could also be wedge-shaped or possess other cross-sectional shapes to conform to the shape of different types of organ.

Abstract

La présente invention concerne un appareil à perfuser les organes. Cet appareil, réalisé autour d'un ordinateur, permet, à des températures quasi normales, de perfuser des organes (1) avec du sang ou d'autres substances véhiculant de l'oxygène. Grâce à des mesures en ligne de caractéristiques de fonctionnement physiologique, l'appareil permet de dresser un bilan de la viabilité de l'organe. Des réalisations de l'appareil mettent en ÷uvre une pompe à sang (30) pilotée par un ordinateur, laquelle pompe permet de réaliser des conditions de perfusion de type physiologique. Afin de favoriser la conservation ou récupération des organes, l'appareil préserve la possibilité (48) de remplacer des volumes de fluide circulatoire et de transfuser des nutriments, des médicaments, ainsi qu'une solution de perfusion modifiée. L'appareil permet également de mesurer au moyen de sondes les tensions de gaz contenus dans la solution de perfusion, le pH, et la température, sans phénomène de brouillage réciproque de nature électrique (15 et 16), de mesurer automatiquement le débit de production d'urine, de bile, des sécrétions du canal pancréatique, ou d'autres exsudats physiologiques (8), et enfin de déterminer les débits de sang ou de solution de perfusion de l'organe, la résistance vasculaire et l'÷dème de l'organe.
PCT/US1996/004205 1995-03-27 1996-03-27 Dispositif et procede de bilan et de reanimation d'organe WO1996029865A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU53754/96A AU5375496A (en) 1995-03-27 1996-03-27 Organ evaluation and resuscitation device and method

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41122795A 1995-03-27 1995-03-27
US08/411,227 1995-03-27

Publications (2)

Publication Number Publication Date
WO1996029865A1 WO1996029865A1 (fr) 1996-10-03
WO1996029865A9 true WO1996029865A9 (fr) 1996-12-05

Family

ID=23628093

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/004205 WO1996029865A1 (fr) 1995-03-27 1996-03-27 Dispositif et procede de bilan et de reanimation d'organe

Country Status (2)

Country Link
AU (1) AU5375496A (fr)
WO (1) WO1996029865A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8962303B2 (en) 1998-09-29 2015-02-24 Lifeline Scientific, Inc. Apparatus and method for maintaining and/or restoring viability of organs

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6375613B1 (en) * 1994-05-20 2002-04-23 Breonics, Inc. Prognostic testing of organs intended for transplantation
US6642045B1 (en) * 1997-04-14 2003-11-04 Breonics, Inc. System for exsanguinous metabolic support of an organ or tissue
ATE253819T1 (de) * 1997-09-23 2003-11-15 Waleed H Hassanein Zusammensetzungen, verfahren unfd geräte zur organerhaltung
US6100082A (en) * 1997-09-23 2000-08-08 Hassanein; Waleed H. Perfusion apparatus and method including chemical compositions for maintaining an organ
US8409846B2 (en) 1997-09-23 2013-04-02 The United States Of America As Represented By The Department Of Veteran Affairs Compositions, methods and devices for maintaining an organ
EP1929863B1 (fr) * 1998-09-29 2016-11-09 Organ Recovery Systems, Inc. Appareil et procédé pour maintenir et/ou restaurer la viabilité d'organes
US6673594B1 (en) * 1998-09-29 2004-01-06 Organ Recovery Systems Apparatus and method for maintaining and/or restoring viability of organs
DE19911326A1 (de) * 1999-03-15 2000-09-28 Fege Wolfgang Vorrichtung zum Züchten von menschlichem oder tierischem Gewebe
US6582953B2 (en) 1999-04-14 2003-06-24 Breonics, Inc. Organ chamber for exsanguinous metabolic support system
WO2002089571A1 (fr) * 2001-05-04 2002-11-14 Breonics, Inc. Compartiment pour organe destine a un systeme de support metabolique exsanguin
AU2003262836A1 (en) 2002-08-23 2004-03-11 Organ Recovery Systems Connectors, particularity for transplant organs
US7504201B2 (en) * 2004-04-05 2009-03-17 Organ Recovery Systems Method for perfusing an organ and for isolating cells from the organ
US9301519B2 (en) 2004-10-07 2016-04-05 Transmedics, Inc. Systems and methods for ex-vivo organ care
US12010987B2 (en) 2004-10-07 2024-06-18 Transmedics, Inc. Systems and methods for ex-vivo organ care and for using lactate as an indication of donor organ status
AU2005294206B2 (en) 2004-10-07 2012-06-14 Transmedics, Inc. Systems and methods for Ex-Vivo organ care
US8304181B2 (en) 2004-10-07 2012-11-06 Transmedics, Inc. Method for ex-vivo organ care and for using lactate as an indication of donor organ status
US9078428B2 (en) 2005-06-28 2015-07-14 Transmedics, Inc. Systems, methods, compositions and solutions for perfusing an organ
US9457179B2 (en) 2007-03-20 2016-10-04 Transmedics, Inc. Systems for monitoring and applying electrical currents in an organ perfusion system
US9247728B2 (en) 2008-01-31 2016-02-02 Transmedics, Inc. Systems and methods for ex vivo lung care
WO2010036726A1 (fr) * 2008-09-23 2010-04-01 Cedars-Sinai Medical Center Procédés et appareil d'irrigation sanguine d'un cœur de donneur explanté
DE102009021099B4 (de) * 2009-05-13 2011-04-21 Siemens Aktiengesellschaft Perfusionsmessphantom und Verwendung eines Perfusionsmessphantoms zur Entwicklung von Kontrastmittelapplikationen für ein bildgebendes Tomographiegerät sowie Verfahren zur Konservierung eines Organs eines toten Lebewesens zur Verwendung in einem solchen Perfusionsmessphantom
CA3106469A1 (fr) 2011-04-14 2012-10-18 Transmedics, Inc. Solution ocs pour perfusion ex vivo de greffons pulmonaires
US9642625B2 (en) 2011-04-29 2017-05-09 Lifeline Scientific, Inc. Cannula for a donor organ with or without an aortic cuff or patch
US8828034B2 (en) 2011-04-29 2014-09-09 Lifeline Scientific, Inc. Cannula
US9022978B2 (en) 2011-04-29 2015-05-05 Lifeline Scientific, Inc. Universal sealring cannula
GB201119420D0 (en) 2011-11-10 2011-12-21 Organox Ltd Oxygen supply for organ perfusion systems
CN104039135B (zh) 2011-11-10 2016-01-20 奥加诺克斯有限责任公司 器官灌注系统
CN104039137B (zh) 2011-11-10 2017-03-08 奥加诺克斯有限责任公司 器官灌注系统
US10602740B2 (en) * 2012-07-10 2020-03-31 Lifeline Scientific, Inc. Organ perfusion apparatus with downstream flow control
CN113287600B (zh) 2014-06-02 2022-08-19 特兰斯迈迪茨公司 对离体肝脏灌注的灌注回路和系统以及对其保存的系统
BR112017010520B1 (pt) 2014-12-12 2022-08-30 Tevosol, Inc Aparelho e método para perfusão de órgãos
JP6883910B2 (ja) * 2015-01-15 2021-06-09 ハイバーニア メディカル エルエルシー 熱発生に基づいた器官の局所的な代謝速度を推定するための、および潅流された組織の容量に対する局所的血流を推定するためのデバイス
IL310004A (en) 2015-09-09 2024-03-01 Transmedics Inc A tube and a catheter for a system to treat organs outside the body
EP3484286A4 (fr) * 2016-07-13 2020-07-22 The Trustees of Columbia University in the City of New York Plate-forme de circulation croisée pour la récupération, la régénération et le maintien d'organes extracorporels
ES2675882B1 (es) * 2017-01-12 2019-04-26 Ebers Medical Tech S L Equipo de perfusion de organos
GB2591784A (en) * 2020-02-06 2021-08-11 Univ Strathclyde Organ transport apparatus
WO2022137164A1 (fr) 2020-12-22 2022-06-30 Polbionica Sp. Z O.O. Système de stockage ou de culture d'un organe ou d'un modèle de tissu et utilisations de celui-ci

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE755423A (fr) * 1969-10-06 1971-02-01 Baxter Laboratories Inc Procede et appareil pour la conservation d'organes
US4231354A (en) * 1978-07-14 1980-11-04 Howmedica, Incorporated Pulsatile blood pumping apparatus and method
US4666425A (en) * 1985-12-17 1987-05-19 The Dis Corporation Device for perfusing an animal head
US5051352A (en) * 1987-10-07 1991-09-24 The Regents Of The University Of California Apparatus and method of preserving the viability of animal organs
CA2001553A1 (fr) * 1988-10-26 1990-04-26 Karen Mckelvey Dispositif pour le transport d'organes humains en vue de transplantations
JPH02258701A (ja) * 1989-03-31 1990-10-19 Olympus Optical Co Ltd 臓器保存装置
JPH0653160B2 (ja) * 1989-08-18 1994-07-20 呉羽化学工業株式会社 拍動発生方法及び装置
FR2667297B1 (fr) * 1990-09-28 1994-05-27 Electrolux Sarl Conteneur medical climatise.
US5217860A (en) * 1991-07-08 1993-06-08 The American National Red Cross Method for preserving organs for transplantation by vitrification
US5338662A (en) * 1992-09-21 1994-08-16 Bio-Preserve Medical Corporation Organ perfusion device

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8962303B2 (en) 1998-09-29 2015-02-24 Lifeline Scientific, Inc. Apparatus and method for maintaining and/or restoring viability of organs

Similar Documents

Publication Publication Date Title
WO1996029865A9 (fr) Dispositif et procede de bilan et de reanimation d'organe
WO1996029865A1 (fr) Dispositif et procede de bilan et de reanimation d'organe
EP0777413B1 (fr) Procede de preparation d'organes en vue de leur cryopreservation
JP6347565B2 (ja) 臓器を維持するための組成物、方法及び装置
CA2113119C (fr) Appareil et methode de perfusion de cryoprotecteur assistee par ordinateur
EP0376763A2 (fr) Dispositif de transport d'organes humains destinés à la transplantation
JP2849473B2 (ja) 器官、身体末端及び身体組織片を保存するための方法及び装置
JP2020193219A (ja) ｅｘ−ｖｉｖｏでの臓器管理システム
WO1988005261A1 (fr) Systeme de perfusion totale pour organes
WO1996041525A2 (fr) Appareil de perfusion d'agents de cryoprotection commande par ordinateur
JP2004513889A (ja) 臓器の生存力を維持及び／又は回復する装置及び方法
WO1996041525A9 (fr) Appareil de perfusion d'agents de cryoprotection commande par ordinateur
US20210259240A1 (en) System and Method for Organ Maintenance and Transport
US20230284613A1 (en) System and method for tissue maintenance, assessment, maturation, and rehabilitation
Arnaud et al. Normothermic Blood Perfusion of Isolated Rabbit Kidneys I. In vitro Analysis of Renal Function